Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01393119 | Phase II, Dose Finding Study of GTx-758 | terminated | Phase 2 | 77 | GTxINDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04677855 | Study of PCUR-101 in Combination With ADT in Patients With mCRPC | terminated | Phase 1 | 7 | Pellficure Pharmaceuticals, IncINDUSTRY | 2 | Apr 10, 2024 | clinicaltrials |
| NCT03810105 |
| A Study of Olaparib and Durvalumab in Prostate Cancer |
| terminated |
| Phase 2 |
| 5 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Apr 9, 2024 |
| clinicaltrials |
| NCT04586335 | Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | terminated | Phase 1 | 24 | Haihe Biopharma Co., Ltd.INDUSTRY | 3 | Mar 21, 2024 | clinicaltrials |
| NCT03657108 | CivaSheet With Radical Prostatectomy & Adjuvant External Beam Radiation | terminated | N/A | 6 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT02933801 | ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents. | terminated | Phase 2 | 92 | Swiss Cancer InstituteOTHER | 4 | Mar 13, 2024 | clinicaltrials |
| NCT03533946 | Rucaparib in Nonmetastatic prOstAte With BRCAness(ROAR) | terminated | Phase 2 | 7 | University of UtahOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05169372 | Retrospective Analysis of 68Ga-PSMA-PET in Patients With Prostate Cancer: Experience From Brazil(PET-PSMA) | terminated | — | 12 | Latin American Cooperative Oncology GroupOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT04727736 | 18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer | terminated | Phase 2 | 47 | Ashok MuthukrishnanOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02279693 | Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer(PROSTRACK) | terminated | N/A | 3 | Centre Georges Francois LeclercOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT03577028 | Study of HPN424 in Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 104 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 2 | Feb 14, 2024 | clinicaltrials |
| NCT02995330 | Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04844749 | Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent(VERACITY) | terminated | Phase 3 | 105 | Veru Inc.INDUSTRY | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04264208 | HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer | terminated | Phase 2 | 4 | Andrei IagaruOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT01996696 | Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate(PREMIUM) | terminated | Phase 2 | 83 | AHS Cancer Control AlbertaOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05673109 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 8 | Accutar Biotechnology IncINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04234399 | Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy | terminated | — | 22 | University of VermontOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05124795 | IMU-935 in Patients With Progressive, Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 18 | Immunic AGINDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04528199 | [18F]FLOR (FC303) PET/CT Imaging in Patients With Prostate Cancer | terminated | Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04409288 | Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer | terminated | Phase 3 | 74 | Chinese University of Hong KongOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT00176631 | Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 10 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT00633087 | A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer(2-Deoxyglucose) | terminated | Phase 1 / Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT03837353 | A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1 | terminated | Phase 1 / Phase 2 | 18 | NYU Langone HealthOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04033328 | Study of ORIC-101 in Combination With Enzalutamide | terminated | Phase 1 | 41 | ORIC PharmaceuticalsINDUSTRY | 1 | Dec 15, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03550040 | 3D Versus Robot Assisted Laparoscopic Prostatectomy. | terminated | N/A | 155 | Tampere University HospitalOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT05910697 | Clinical Utility of MyProstateScore 2.0 P2 | terminated | N/A | 142 | Qure Healthcare, LLCINDUSTRY | 1 | Nov 15, 2023 | clinicaltrials |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT02616185 | A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) | terminated | Phase 1 | 91 | PfizerINDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03619655 | Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy | terminated | Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03824808 | Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery | terminated | Phase 4 | 21 | University of Missouri-ColumbiaOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02626377 | Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté(ICE) | terminated | N/A | 186 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03180398 | Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients | terminated | N/A | 9 | Henry Ford Health SystemOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT01420861 | GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer | terminated | Phase 2 | 18 | GTxINDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT00769652 | Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer | terminated | N/A | 8 | Rutgers, The State University of New JerseyOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01377389 | Ipilimumab + Androgen Depravation Therapy in Prostate Cancer | terminated | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 80 | Veru Inc.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT00176644 | Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT00483561 | Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 26 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT02809690 | 18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer | terminated | Phase 1 | 18 | University of Southern CaliforniaOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05437679 | Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System(CHARTER) | terminated | — | 9 | Angle plcINDUSTRY | 1 | Sep 5, 2023 | clinicaltrials |
| NCT00499174 | Observation or Radical Treatment in Patients With Prostate Cancer | terminated | N/A | 180 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 23, 2023 | clinicaltrials |
| NCT04227275 | A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 | 16 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 21, 2023 | clinicaltrials |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 1 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 22, 2024source: clinicaltrials